A randomized study of intermediate versus conventional‐dose cytarabine as intensive induction for acute myelogenous leukaemia

Gary Schiller, James Gajewski, Stephen Nimer, Mary Territo, Winston Ho, Myung Lee, Richard Champlin

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

The optimal dose of cytarabine for induction chemotherapy is unknown. Most studies have utilized doses of 100-200 mg/m2/d, although higher doses have been proposed to increase the concentration of the active metabolite ara-CTP within leukaemia cells. To address this question 101 adults with newly diagnosed acute myeloid leukaemia were randomized to receive treatment with daunorubicin and either conventional-dose cytarabine (200 mg/m2/d by continuous infusion) or an intermediate-dose of cytarabine (500 mg/m2 every 12 h). 36/51 (71%) patients assigned to conventional-dose cytarabine achieved complete remission compared to 37/50 (74%) who achieved remission with intermediate-dose cytarabine (P = 0.9). Patient age significantly affected remission rate. 8/17 patients age > 60 assigned to conventional-dose cytarabine and 10/17 assigned to intermediate-dose cytarabine achieved complete remission compared to 27/33 patients under age 60 assigned to the conventional dose and 28/34 patients assigned to the intermediate dose arm (P = 0.004). Actuarial 4-year disease-free survival for patients assigned to conventional-dose cytarabine was 20 ± 16% versus 28 ± 17% for patients assigned to intermediate-dose cytarabine (P = 0.9). We conclude that intermediate dose cytarabine did not substantially improve results of induction chemotherapy for acute myeloid leukaemia.

Original languageEnglish (US)
Pages (from-to)170-177
Number of pages8
JournalBritish Journal of Haematology
Volume81
Issue number2
DOIs
StatePublished - Jun 1992
Externally publishedYes

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'A randomized study of intermediate versus conventional‐dose cytarabine as intensive induction for acute myelogenous leukaemia'. Together they form a unique fingerprint.

  • Cite this